Do answers to the mysteries of cancer lie hidden within the DNA of tumor cells? Researchers think so.
Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.
Novartis is one of this year’s top 20 employers in an annual survey from Science.
The incidence of leprosy, an infectious disease that causes lumps and skin sores, has decreased by roughly 95%, but 233,000 new cases were reported in 2012.
US Pharmaceutical Division chosen for the magazine’s 2013 list of best employers for mothers.
Professor Klaus M. Leisinger is stepping down as Chairman of the Board of the Novartis Foundation for Sustainable Development (NFSD). Dr. Andrin Oswald will take on an additional role as Chairman of the Board overseeing the NFSD.
Malaria programs in sub-Saharan Africa are making progress by using insecticide-treated nets, diagnostic testing and Artemisinin-based Combination Therapy.
More than 1.5 million healthcare workers, including nurses and birthing attendants, are needed in Africa. The continent has 24% of the world’s disease burden.
Ad hoc announcement pursuant to article 53 Listing Rules.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.